[go: up one dir, main page]

JPH0557015A - Adsorbent and sterilizing method therefor - Google Patents

Adsorbent and sterilizing method therefor

Info

Publication number
JPH0557015A
JPH0557015A JP3250191A JP25019191A JPH0557015A JP H0557015 A JPH0557015 A JP H0557015A JP 3250191 A JP3250191 A JP 3250191A JP 25019191 A JP25019191 A JP 25019191A JP H0557015 A JPH0557015 A JP H0557015A
Authority
JP
Japan
Prior art keywords
adsorbent
aqueous solution
sulfate
pressure steam
sulfated polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3250191A
Other languages
Japanese (ja)
Inventor
Hajime Yoshida
一 吉田
Norio Inama
徳生 稲摩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Medical Co Ltd
Original Assignee
Asahi Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Medical Co Ltd filed Critical Asahi Medical Co Ltd
Priority to JP3250191A priority Critical patent/JPH0557015A/en
Publication of JPH0557015A publication Critical patent/JPH0557015A/en
Pending legal-status Critical Current

Links

Landscapes

  • Apparatus For Disinfection Or Sterilisation (AREA)
  • External Artificial Organs (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

PURPOSE:To provide a blood purification adsorbent having a sulfated polysaccharide on the surface thereof for adsorbing and removing a harmful ingredient from blood, and a sterilizing method of high safety therefor, ensuring freedom from a drop in adsorption and elimination capability due to high pressure steam sterilization. CONSTITUTION:A blood purification adsorbent having a sulfated polysaccharide on the surface thereof is sterilized under high pressure steam in water solution containing 0.001 to 10% of pyrosulfurous acid and/or a salt thereof and having a pH value controlled within the range of 5 to 9.5.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、血液中の有害成分を吸
着除去するための硫酸化多糖類を表面に有する血液浄化
用吸着剤とその滅菌方法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an adsorbent for blood purification having on its surface a sulfated polysaccharide for adsorbing and removing harmful components in blood, and a sterilizing method thereof.

【0002】[0002]

【従来の技術】血液中の有害成分除去の目的に、該有害
成分に対して親和性のある物質、即ちリガンドを共有結
合によって水不溶性担体に固定した吸着剤を、臨床的に
利用しようとする試みが成されている。
2. Description of the Related Art For the purpose of removing harmful components in blood, a substance having an affinity for the harmful components, that is, an adsorbent in which a ligand is immobilized on a water-insoluble carrier by a covalent bond, is clinically utilized. Attempts have been made.

【0003】これら吸着剤を臨床に用いるためには滅菌
が不可欠である。この滅菌方法としては取扱い性、安全
性の点で高圧蒸気滅菌が好ましい。しかしこれら吸着剤
を高圧蒸気滅菌するとリガンドの失活や脱離が起こり、
その結果、吸着剤の有する除去性能の大幅な低下を伴
い、かつ臨床施行時の安全性の点でも問題がある。特
に、デキストラン硫酸などの硫酸化多糖類では、高圧蒸
気滅菌時の熱による硫酸化多糖類と水不溶性担体との共
有結合部分の開裂と硫酸化多糖類分子自体の分解、その
分解の過程で生じた硫酸化合物により更に加速的に自己
分解が進んでしまうと考えられる。
Sterilization is indispensable for clinical use of these adsorbents. As the sterilization method, high-pressure steam sterilization is preferable from the viewpoints of handleability and safety. However, high pressure steam sterilization of these adsorbents causes deactivation and desorption of ligands,
As a result, the removal performance of the adsorbent is greatly reduced, and there is a problem in safety in clinical practice. Particularly, in the case of sulfated polysaccharides such as dextran sulfate, the covalent bond between the sulfated polysaccharide and the water-insoluble carrier is cleaved by heat during high-pressure steam sterilization, the sulfated polysaccharide molecule itself is decomposed, and occurs in the process of its decomposition. It is considered that the sulfuric acid compound further accelerates the self-decomposition.

【0004】ところで硫酸化多糖類を表面に有する吸着
剤の高圧蒸気滅菌をクエン酸、リン酸、酢酸、ホウ酸、
酒石酸、炭酸、マレイン酸、グリシンの内の少なくとも
1種を用いたpH5〜9の緩衝液中で行うことによって
硫酸化多糖類の分解を少なくしようとする試みがある
(特開昭61−100261号)。 しかしながら上記方法はなるほど生成された硫酸化合物
によるpH低下に起因する自己分解は防止し得るが、熱
そのものによる分解を防止するものではなく、かなりの
性能の低下とリガンドの脱離があり大きな問題であっ
た。
By the way, high pressure steam sterilization of an adsorbent having a sulfated polysaccharide on its surface is carried out by citric acid, phosphoric acid, acetic acid, boric acid,
There has been an attempt to reduce the decomposition of sulfated polysaccharides by carrying out in a buffer solution of at least one of tartaric acid, carbonic acid, maleic acid and glycine at pH 5 to 9 (JP-A-61-100261). ). However, although the above-mentioned method can prevent self-decomposition due to pH decrease due to the generated sulfuric acid compound, it does not prevent decomposition due to heat itself, and there is a considerable decrease in performance and desorption of ligand, which is a serious problem. there were.

【0005】[0005]

【発明が解決しようとする課題】本発明者らがより優れ
た滅菌方法を見いだすべく鋭意研究した結果、硫酸化多
糖類を表面に有する血液浄化用吸着剤を高圧蒸気滅菌す
るに当たり、ピロ亜硫酸または/及びその塩を0.00
1〜10%含む水溶液中で行うことによって吸着剤の有
する除去性能の低下を抑制できる、という画期的な事実
を見い出し、除去性能の低下が無い、安全性にも優れた
吸着剤を発明するに至った。
DISCLOSURE OF THE INVENTION As a result of intensive studies conducted by the present inventors to find a better sterilization method, it was found that pyrosulfite or / And its salt 0.00
We have found an epoch-making fact that the removal performance of adsorbents can be suppressed from decreasing by carrying out in an aqueous solution containing 1 to 10%, and we invent an adsorbent that is free from deterioration of removal performance and excellent in safety. Came to.

【0006】[0006]

【課題を解決するための手段】すなわち本発明の要旨
は、ピロ亜硫酸または/及びその塩を0.001〜10
%含み、pHが5〜9.5の範囲に調整された水溶液中
で高圧蒸気滅菌を行うことを特徴とする、硫酸化多糖類
を表面に有する血液浄化用吸着剤の滅菌方法、及びこの
滅菌方法によって得られた血液浄化用吸着剤にある。
That is, the gist of the present invention is to provide pyrosulfite or / and its salt in an amount of 0.001-10.
%, And high-pressure steam sterilization in an aqueous solution whose pH is adjusted to a range of 5 to 9.5, and a method for sterilizing an adsorbent for blood purification having a sulfated polysaccharide on its surface, and this sterilization In the adsorbent for blood purification obtained by the method.

【0007】本発明者らが種々研究した結果によると、
ピロ亜硫酸または/及びその塩は、高圧蒸気滅菌時の熱
による硫酸化多糖類と水不溶性担体との共有結合部分の
開裂と、硫酸化多糖類分子自体の分解の両者に対して防
止効果があると考えられる。
According to the results of various studies by the present inventors,
Pyrosulfurous acid and / or its salt have an effect of preventing both the cleavage of the covalent bond between the sulfated polysaccharide and the water-insoluble carrier due to heat during high-pressure steam sterilization and the decomposition of the sulfated polysaccharide molecule itself. it is conceivable that.

【0008】本発明をより詳細に説明すると、ピロ亜硫
酸または/及びその塩の濃度は0.001〜10%であ
ることが望ましい。更に望ましくは0.01〜2%の範
囲がよい。この時、アルカリ性物質によってpH5〜
9.5であることが低pHでの自己分解を防止するため
に有効であり、この両者の組み合わせではじめて優れた
滅菌方法となり得る。
To explain the present invention in more detail, it is desirable that the concentration of pyrosulfite or / and its salt is 0.001 to 10%. More preferably, the range is 0.01 to 2%. At this time, depending on the alkaline substance,
A value of 9.5 is effective for preventing self-decomposition at low pH, and an excellent sterilization method can be achieved only by combining these two.

【0009】pHが5〜9.5であることとは滅菌直後
の水溶液のpHが5〜9.5であることを言う。滅菌前
のpHは、5〜9.5であることが望ましいが、吸着剤
を水溶液に浸漬後速やかに滅菌を行う場合は必ずしも限
定されない。但し、pH4.5以下では硫酸化多糖類の
分解が速やかであるため滅菌前のpHは5以上であるこ
とが好ましい。
The pH of 5 to 9.5 means that the pH of the aqueous solution immediately after sterilization is 5 to 9.5. The pH before sterilization is preferably 5 to 9.5, but is not necessarily limited to the case where the adsorbent is immersed in an aqueous solution and then rapidly sterilized. However, the pH before sterilization is preferably 5 or higher because the sulfated polysaccharide is rapidly decomposed at pH 4.5 or lower.

【0010】水溶液のpHを5〜9.5とするには、ア
ルカリ金属またはアルカリ土類金属の炭酸化物、水酸化
物、或いは炭酸水素化合物など、例えば炭酸ナトリウ
ム、炭酸水素ナトリウム、水酸化ナトリウム、水酸化カ
リウムなどの塩基性物質を該水溶液中に加えることによ
ってできる。この時の至適な塩基性物質の濃度はピロ亜
硫酸または/及びその塩の濃度によって変わり、必ずし
も特定できないが、通常0.001〜5%が好ましく用
いることができ、特により好ましい範囲をあげるならば
0.005〜1.5%である。
To adjust the pH of the aqueous solution to 5 to 9.5, alkali metal or alkaline earth metal carbonates, hydroxides, or hydrogen carbonate compounds, such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, This can be done by adding a basic substance such as potassium hydroxide into the aqueous solution. The optimum concentration of the basic substance at this time varies depending on the concentration of pyrosulfurous acid or / and its salt and cannot be specified. However, usually 0.001 to 5% can be preferably used, and if a particularly preferable range is mentioned, For example, it is 0.005 to 1.5%.

【0011】本発明者らの研究によると、この中で特に
炭酸ナトリウムと炭酸水素ナトリウムが取扱い性も考慮
して最も良好であった。あえて最も良好な例をあげる
と、ピロ亜硫酸ナトリウム0.01〜0.2%、炭酸ナ
トリウム0.005〜0.2%である。
According to the research conducted by the present inventors, sodium carbonate and sodium hydrogencarbonate were the best among these, considering the handling property. The most preferable examples are 0.01-0.2% sodium pyrosulfite and 0.005-0.2% sodium carbonate.

【0012】本発明でいう硫酸化多糖類を表面に有する
血液浄化用吸着剤とは、硫酸化多糖類を共有結合を介し
て水不溶性担体に不溶化したものである。水不溶性担体
の形状としては球状、粒状、糸状、中空糸状、平膜状な
どいずれも有効に使用できる。この中で球状又は粒状の
ものが、単位容積あたりの吸着面積を多くとれるので最
も好ましい。
The adsorbent for blood purification having a sulfated polysaccharide on its surface as used in the present invention is an adsorbent in which a sulfated polysaccharide is insolubilized in a water-insoluble carrier through a covalent bond. As the shape of the water-insoluble carrier, any of spherical shape, granular shape, thread shape, hollow fiber shape, flat membrane shape and the like can be effectively used. Among these, spherical or granular ones are most preferable because they can have a large adsorption area per unit volume.

【0013】球状又は粒状の平均粒径は、10〜2,5
00μmのものが使いやすいが、25〜1,000μm
の範囲のものが好ましい。水不溶性担体は、有害成分の
吸着面積を大きくとれ、実用的な吸着能力を出せるとい
う観点から、多孔性であることが好ましい。多孔性の排
除限界分子量は、吸着しようとする有害成分の分子量に
よって異なるが、1×104 以上、1×108 以下のも
のが好ましい。更に限定するならば、1×105 以上、
5×107 以下のものがより好ましい。
The spherical or granular average particle size is 10 to 2,5.
It is easy to use the one of 00 μm, but it is 25-1,000 μm
The range of is preferable. The water-insoluble carrier is preferably porous from the viewpoint that a large adsorption area for harmful components can be obtained and a practical adsorption capacity can be obtained. The exclusion limit molecular weight of porosity depends on the molecular weight of the harmful component to be adsorbed, but is preferably 1 × 10 4 or more and 1 × 10 8 or less. To further limit, 1 × 10 5 or more,
It is more preferably 5 × 10 7 or less.

【0014】水不溶性担体の具体例を挙げると、例えば
アガロース、デキストラン、ポリアクリルアミド等から
なる軟質ゲル、メチルメタクリレート、ポリビニルアル
コール、スチレン、ジビニルベンゼン、ビニルエーテ
ル、無水マレイン酸、ポリアミド等の内の一つまたは複
数を構成成分とする合成高分子、または/及びセルロー
ス等の天然高分子を原料とする多孔質ポリマーからなる
硬質ゲルなどである。更に、ヒドロキシエチルメタクリ
レート、ヒドロキシエチルアクリレート等のヒドロキシ
基を有する高分子材料、ビニルアミン、ジメチルアミノ
エチル(メタ)アクリレート等の塩基性含窒素官能基を
有する単量体と塩基性含窒素官能基を有さない重合性単
量体との共重合体、スルフォン酸基、カルボン酸基等の
負電荷官能基を有する高分子材料、セグメント化ポリウ
レタン、セグメント化ポリエステル等のブロック共重合
体、ポリエチレンオキサイド鎖を有する単量体と他の重
合性単量体との共重合体の様なグラフト共重合体等の表
面層を有していても良い。
Specific examples of the water-insoluble carrier include, for example, one of soft gels made of agarose, dextran, polyacrylamide, etc., methyl methacrylate, polyvinyl alcohol, styrene, divinylbenzene, vinyl ether, maleic anhydride, polyamide, etc. Alternatively, a synthetic polymer having a plurality of constituents, and / or a hard gel made of a porous polymer obtained from a natural polymer such as cellulose as a raw material. Further, a polymer material having a hydroxy group such as hydroxyethyl methacrylate and hydroxyethyl acrylate, a monomer having a basic nitrogen-containing functional group such as vinylamine and dimethylaminoethyl (meth) acrylate, and a basic nitrogen-containing functional group are included. A copolymer with a polymerizable monomer, a polymer material having a negatively charged functional group such as a sulfonic acid group or a carboxylic acid group, a segmented polyurethane, a block copolymer such as a segmented polyester, or a polyethylene oxide chain. It may have a surface layer such as a graft copolymer such as a copolymer of the monomer having it and another polymerizable monomer.

【0015】これらの内、硬質ゲルが体液の流通性の観
点より好ましく用いられる。更により好ましくはポリビ
ニルアルコール等からなる合成高分子の硬質ゲルが、ゲ
ル表面に活性基を比較的容易に得られるため実用状好ま
しい。硫酸化多糖類と共有結合する水不溶性担体表面の
活性基は、硫酸化多糖類の水酸基、カルボキシル基など
の活性水素を有する反応性基と置換または/及び付加反
応できるものであれば良い。
Of these, hard gels are preferably used from the viewpoint of the flowability of body fluids. Still more preferably, a synthetic polymer hard gel made of polyvinyl alcohol or the like is preferable for practical use because an active group can be relatively easily obtained on the gel surface. The active group on the surface of the water-insoluble carrier that is covalently bonded to the sulfated polysaccharide may be any group that can be substituted or / and addition-reacted with a reactive group having an active hydrogen such as a hydroxyl group or a carboxyl group of the sulfated polysaccharide.

【0016】水不溶性担体に活性基を得る方法の一例と
してはハロゲン化シアン法、エピクロルヒドリン法、ビ
スエポキシド法、ブロモアセチルブロミド法等が知られ
ている。具体的にはアミノ基、カルボキシル基、ヒドロ
キシル基、チオール基、酸無水物基、サクシニルイミド
基、塩素基、アルデヒド基、アミド基、エポキシ基など
があげられる。
Known examples of methods for obtaining an active group on a water-insoluble carrier include a cyanogen halide method, an epichlorohydrin method, a bisepoxide method, and a bromoacetyl bromide method. Specific examples thereof include an amino group, a carboxyl group, a hydroxyl group, a thiol group, an acid anhydride group, a succinylimide group, a chlorine group, an aldehyde group, an amide group and an epoxy group.

【0017】この中で加熱滅菌時の安定性よりエピクロ
ルヒドリン法などで誘導されるエポキシ基が特に好まし
い例としてあげられる。以上の活性基を介して共有結合
される硫酸化多糖類とは、その分子中に硫酸基を持つ多
糖類であって、ヘパリン、デキストラン硫酸、コンドロ
イチン硫酸、コンドロイチンポリ硫酸、ヘパラン硫酸、
ケラタン硫酸、ヘパリチン硫酸、キシラン硫酸、カロニ
ン硫酸、セルロース硫酸、キチン硫酸、キトサン硫酸、
ペクチン硫酸、イヌリン硫酸、アルギン酸硫酸、グリコ
ーゲン硫酸、ポリラクトース硫酸、カラゲニン硫酸、デ
ンプン硫酸、ポリグルコース硫酸、ラミラリン硫酸、ガ
ラクタン硫酸、レバン硫酸、メペサルフェート等があげ
られる。この中で特に臨床での実用性の点より最も好ま
しい例としてヘパリンやデキストラン硫酸があげられ
る。
Of these, an epoxy group derived from the epichlorohydrin method or the like is particularly preferable because of its stability during heat sterilization. The sulfated polysaccharide covalently bound through the above active group is a polysaccharide having a sulfate group in its molecule, heparin, dextran sulfate, chondroitin sulfate, chondroitin polysulfate, heparan sulfate,
Keratan sulfate, heparitin sulfate, xylan sulfate, caronine sulfate, cellulose sulfate, chitin sulfate, chitosan sulfate,
Examples thereof include pectin sulfate, inulin sulfate, alginate sulfate, glycogen sulfate, polylactose sulfate, carrageenin sulfate, starch sulfate, polyglucose sulfate, ramillarin sulfate, galactan sulfate, levan sulfate, and mepesulfate. Of these, heparin and dextran sulfate are the most preferable examples from the viewpoint of clinical practicality.

【0018】これらの硫酸化多糖類の分子量はいずれの
分子量であっても良いが、あえてあげるならばリガンド
としての性能の点より分子量5,000以上のものが特
によい。
The molecular weight of these sulfated polysaccharides may be any molecular weight, but if it is dared to say, a molecular weight of 5,000 or more is particularly preferable from the viewpoint of performance as a ligand.

【0019】以上の、ピロ亜硫酸または/及びその塩を
0.001〜10%含む水溶液中に充填された、硫酸化
多糖類を表面に有する血液浄化用吸着剤の用途として
は、低密度または/及び極低密度リポ蛋白質、スルファ
チド付着性蛋白質、活性化補体成分、アミロイド蛋白
A、免疫複合体、抗DNA抗体やリウマチ因子等の自己
抗体または/及び該自己抗体を生産する免疫B細胞、免
疫グロブリンL鎖、血液凝固第VIII因子、血液凝固第IX
因子、β2 ミクログロブリン等があげられる。この中で
低密度または/及び極低密度リポ蛋白質の吸着剤として
の用途が臨床上の有用性が高い。
The above-mentioned adsorbent for blood purification having a sulfated polysaccharide on the surface, which is filled in an aqueous solution containing 0.001 to 10% of pyrosulfurous acid and / or its salt, has a low density or / And extremely low density lipoprotein, sulfatide adhesion protein, activated complement component, amyloid protein A, immune complex, autoantibody such as anti-DNA antibody and rheumatoid factor, and / or immune B cell producing the autoantibody, immunity Globulin L chain, blood coagulation factor VIII, blood coagulation factor IX
Factor, β 2 microglobulin and the like. Among them, the use of low density and / or very low density lipoprotein as an adsorbent is highly clinically useful.

【0020】[0020]

【発明の効果】本発明の、ピロ亜硫酸または/及びその
塩を0.001〜10%含む水溶液中で滅菌することに
よって、これまで滅菌操作時に発生していた性能の低下
を防止でき、しかもリガンドである硫酸化多糖類の脱離
も少ない、優れた品質の吸着剤が得られる。
By sterilizing the present invention in an aqueous solution containing 0.001 to 10% of pyrosulfurous acid and / or a salt thereof, it is possible to prevent the deterioration of the performance which has occurred during the sterilization operation up to now, and the ligand It is possible to obtain an adsorbent of excellent quality with little desorption of sulfated polysaccharides.

【0021】[0021]

【実施例】以下に具体例をあげて説明するが、本発明は
これらに限定されるものではない。
EXAMPLES The present invention will be described below with reference to specific examples, but the present invention is not limited thereto.

【0022】実施例1.トリアリルイソシアヌレートを
架橋剤として用い、リン酸緩衝水溶液中で酢酸ビニルを
懸濁重合して、ポリビニルアルコール共重合体を得た。
得られたポリビニルアルコール共重合体を、水不溶性担
体として用いた。この水不溶性担体は、平均粒径100
μm、単位重量あたりのビニルアルコール単位(qO
H)が6.0meq/g、排除限界分子量5x106
あった。
Example 1. Using triallyl isocyanurate as a cross-linking agent, suspension polymerization of vinyl acetate in a phosphate buffer aqueous solution was performed to obtain a polyvinyl alcohol copolymer.
The obtained polyvinyl alcohol copolymer was used as a water-insoluble carrier. This water-insoluble carrier has an average particle size of 100.
μm, vinyl alcohol unit per unit weight (qO
H) was 6.0 meq / g, and the exclusion limit molecular weight was 5 × 10 6 .

【0023】次にエステル交換して水で十分に洗浄した
後、ジメチルスルフォキシドと水酸化ナトリウム水溶液
の混合液中でエピクロルヒドリンを反応させて、エポキ
シ活性化担体を得た。このエポキシ活性化担体に、エポ
キシ基を介して、分子量500,000、硫黄含量1
8.2wt%のデキストラン硫酸を共有結合させて、デ
キストラン硫酸固定の吸着剤を得た。この吸着剤に固定
されたデキストラン硫酸量は、吸着剤1mlあたり5.
9mgであった。
After transesterification and thorough washing with water, epichlorohydrin was reacted in a mixed solution of dimethyl sulfoxide and an aqueous sodium hydroxide solution to obtain an epoxy activated carrier. This epoxy-activated carrier has a molecular weight of 500,000 and a sulfur content of 1 via an epoxy group.
A dextran sulfate-immobilized adsorbent was obtained by covalently bonding 8.2 wt% of dextran sulfate. The amount of dextran sulfate fixed on this adsorbent was 5.
It was 9 mg.

【0024】この吸着剤10mlを取り、ピロ亜硫酸ナ
トリウム0.02%、炭酸ナトリウム0.016%を含
む水溶液100ml中で、121℃で30分間高圧蒸気
滅菌を行った。この時、滅菌前後のpHと吸着剤1ml
あたりのデキストラン硫酸固定量、コレステロール吸着
除去性能を測定した。コレステロール吸着性能は、コレ
ステロール濃度410mg/d1の人血漿を用いて測定
した。結果を表1に示す。
10 ml of this adsorbent was taken and subjected to high-pressure steam sterilization at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing 0.02% of sodium pyrosulfite and 0.016% of sodium carbonate. At this time, pH before and after sterilization and 1 ml of adsorbent
The fixed amount of dextran sulfate and the adsorption / removal performance of cholesterol were measured. The cholesterol adsorption performance was measured using human plasma with a cholesterol concentration of 410 mg / d1. The results are shown in Table 1.

【0025】[0025]

【表1】 [Table 1]

【0026】実施例2.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.06%、炭酸ナトリウム0.03%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。
Example 2. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was used as an aqueous solution 1 containing sodium pyrosulfite 0.06% and sodium carbonate 0.03%.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.

【0027】実施例3.実施例1得られたデキストラン
硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.05%、炭酸ナトリウム0.06%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。
Example 3. Example 1 10 ml of the obtained dextran sulfate-fixed adsorbent was added to an aqueous solution 1 containing 0.05% sodium pyrosulfite and 0.06% sodium carbonate.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.

【0028】実施例4.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.24%、炭酸ナトリウム0.09%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。
Example 4. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was used as an aqueous solution 1 containing sodium pyrosulfite 0.24% and sodium carbonate 0.09%.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.

【0029】実施例5.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.12%、炭酸ナトリウム0.06%含む水溶液10
0ml中で、121℃で30分間高圧蒸気滅菌を行い、
実施例1と同様吸着性能の測定を行った。結果を表1に
示す。
Example 5. 10 ml of an aqueous solution containing 0.12% of sodium pyrosulfite and 0.06% of sodium carbonate was added to 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1.
Perform high-pressure steam sterilization in 0 ml at 121 ° C for 30 minutes,
The adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.

【0030】実施例6.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
1.00%、炭酸ナトリウム0.50%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。
Example 6. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was treated with an aqueous solution 1 containing sodium pyrosulfite (1.00%) and sodium carbonate (0.50%).
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.

【0031】実施例7.水不溶性担体として、平均粒子
系80μm、排除限界分子量500万のセルロースゲル
(チッソ(株)製)を用い、実施例1と同様にしてデキ
ストラン硫酸固定の吸着剤を得た。
Example 7. A cellulose gel having an average particle size of 80 μm and an exclusion limit molecular weight of 5,000,000 (manufactured by Chisso Corporation) was used as a water-insoluble carrier, and a dextran sulfate-fixed adsorbent was obtained in the same manner as in Example 1.

【0032】この吸着剤に固定されたデキストラン硫酸
量は、吸着剤1mlあたり0.62mgであった。この
でデキストラン硫酸固定の吸着剤10mlを、ピロ亜硫
酸ナトリウム0.12%、炭酸ナトリウム0.06%を
含む水溶液100ml中で、121℃で30分間高圧蒸
気滅菌を行い、実施例1と同様吸着性能の測定を行っ
た。結果を表1に示す。
The amount of dextran sulfate fixed on this adsorbent was 0.62 mg per 1 ml of the adsorbent. Then, 10 ml of the dextran sulfate-fixed adsorbent was subjected to high-pressure steam sterilization at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing sodium pyrosulfite 0.12% and sodium carbonate 0.06%, and the adsorption performance was the same as in Example 1. Was measured. The results are shown in Table 1.

【0033】比較例1.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.24%、炭酸ナトリウム0.06%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様の吸着性能の測定を行った。結果を
表1に示す。
Comparative Example 1. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was used as an aqueous solution 1 containing 0.24% of sodium pyrosulfite and 0.06% of sodium carbonate.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.

【0034】比較例2.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを用いて、リン酸2水素カ
リウム0.27%、リン酸水素2ナトリウム0.67%
を含む水溶液100ml中で、121℃で30分間高圧
蒸気滅菌を行い、実施例1と同様吸着性能の測定を行っ
た。結果を表1に示す。
Comparative Example 2. Using 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1, potassium dihydrogen phosphate 0.27%, disodium hydrogen phosphate 0.67%
High-pressure steam sterilization was carried out at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.

【0035】比較例3.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、リン酸2水素カリウム
0.65%、リン酸水素2ナトリウム0.29%を含む
水溶液100ml中で、121℃で30分間高圧蒸気滅
菌を行い、実施例1と同様吸着性能の測定を行った。結
果を表1に示す。
Comparative Example 3. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was autoclaved at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing 0.65% potassium dihydrogen phosphate and 0.29% disodium hydrogen phosphate. The adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.

【0036】比較例4.実施例7で得られたデキストラ
ン硫酸固定の吸着剤10mlを、リン酸2水素カリウム
0.27%、リン酸水素2ナトリウム0.67%を含む
水溶液100ml中で、121℃で30分間高圧蒸気滅
菌を行い、実施例1と同様吸着性能の測定を行った。結
果を表1に示す。
Comparative Example 4. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 7 was autoclaved at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing 0.27% potassium dihydrogen phosphate and 0.67% disodium hydrogen phosphate. The adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.

【0037】ピロ亜硫酸ナトリウムが存在し、且つpH
が5〜9.5の範囲にある場合には、デキストラン硫酸
固定量とコレステロール吸着除去性能共に、滅菌前後で
ほとんど変化はみられなかった。これに対してピロ亜硫
酸ナトリウムが存在しない例では、pHが5〜9.5の
範囲にある場合でもデキストラン硫酸固定量とコレステ
ロール吸着除去性能共に、滅菌前後で低下がみられた。
更にピロ亜硫酸ナトリウムが存在してもpHが5〜9.
5の範囲に無い場合は、やはりデキストラン硫酸固定量
とコレステロール吸着除去性能共に、滅菌前後で低下が
みられた。
Sodium pyrosulfite is present and pH
In the range of 5 to 9.5, there was almost no change in dextran sulfate fixed amount and cholesterol adsorption / removal performance before and after sterilization. On the other hand, in the example in which sodium pyrosulfite was not present, both the fixed amount of dextran sulfate and the adsorption / removal performance of cholesterol were decreased before and after sterilization even when the pH was in the range of 5 to 9.5.
Furthermore, even if sodium pyrosulfite is present, the pH is 5-9.
When it was not within the range of 5, the dextran sulfate fixed amount and the cholesterol adsorption / removal performance were also decreased before and after sterilization.

Claims (8)

【特許請求の範囲】[Claims] 【請求項1】 ピロ亜硫酸または/及びその塩を0.0
01〜10%含み、pHが5〜9.5の範囲に調整され
た水溶液中で高圧蒸気滅菌を行うことを特徴とする、硫
酸化多糖類を表面に有する血液浄化用吸着剤の滅菌方
法。
1. Pyrosulfurous acid or / and its salt is 0.0
A method for sterilizing an adsorbent for blood purification having a sulfated polysaccharide on the surface, which comprises performing high-pressure steam sterilization in an aqueous solution containing 01 to 10% and having a pH adjusted to a range of 5 to 9.5.
【請求項2】 水溶液に少なくとも1種以上のアルカリ
性物質が0.001〜5%含まれる請求項1記載の吸着
剤の滅菌方法。
2. The method for sterilizing an adsorbent according to claim 1, wherein the aqueous solution contains 0.001 to 5% of at least one alkaline substance.
【請求項3】 アルカリ性物質がアルカリ金属またはア
ルカリ土類金属からなる化合物の少なくとも1種である
請求項2記載の吸着剤の滅菌方法。
3. The method for sterilizing an adsorbent according to claim 2, wherein the alkaline substance is at least one compound selected from alkali metals and alkaline earth metals.
【請求項4】 アルカリ性物質が炭酸ナトリウム、炭酸
水素ナトリウム、水酸化ナトリウム、水酸化カリウムの
少なくとも1種である請求項2記載の吸着剤の滅菌方
法。
4. The method for sterilizing an adsorbent according to claim 2, wherein the alkaline substance is at least one of sodium carbonate, sodium hydrogen carbonate, sodium hydroxide and potassium hydroxide.
【請求項5】 ピロ亜硫酸または/及びその塩を0.0
01〜10%含み、pHが5〜9.5の範囲に調整され
た水溶液中で高圧蒸気滅菌を行ったことを特徴とする、
硫酸化多糖類を表面に有する血液浄化用吸着剤。
5. The amount of pyrosulfurous acid and / or its salt added to 0.0
High pressure steam sterilization was performed in an aqueous solution containing 01 to 10% and having a pH adjusted to a range of 5 to 9.5,
An adsorbent for blood purification having a sulfated polysaccharide on the surface.
【請求項6】 水溶液に少なくとも1種以上のアルカリ
性物質が0.001〜5%含まれる請求項5記載の吸着
剤。
6. The adsorbent according to claim 5, wherein the aqueous solution contains 0.001 to 5% of at least one alkaline substance.
【請求項7】 アルカリ性物質がアルカリ金属またはア
ルカリ土類金属からなる化合物の少なくとも1種である
請求項6記載の吸着剤。
7. The adsorbent according to claim 6, wherein the alkaline substance is at least one compound selected from the group consisting of alkali metals and alkaline earth metals.
【請求項8】 アルカリ性物質が炭酸ナトリウム、炭酸
水素ナトリウム、水酸化ナトリウム、水酸化カリウムの
少なくとも1種である請求項6記載の吸着剤。
8. The adsorbent according to claim 6, wherein the alkaline substance is at least one of sodium carbonate, sodium hydrogen carbonate, sodium hydroxide and potassium hydroxide.
JP3250191A 1991-09-04 1991-09-04 Adsorbent and sterilizing method therefor Pending JPH0557015A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3250191A JPH0557015A (en) 1991-09-04 1991-09-04 Adsorbent and sterilizing method therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3250191A JPH0557015A (en) 1991-09-04 1991-09-04 Adsorbent and sterilizing method therefor

Publications (1)

Publication Number Publication Date
JPH0557015A true JPH0557015A (en) 1993-03-09

Family

ID=17204171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3250191A Pending JPH0557015A (en) 1991-09-04 1991-09-04 Adsorbent and sterilizing method therefor

Country Status (1)

Country Link
JP (1) JPH0557015A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582386B2 (en) 2001-03-06 2003-06-24 Baxter International Inc. Multi-purpose, automated blood and fluid processing systems and methods
US6706008B2 (en) 2001-03-06 2004-03-16 Baxter International Inc. Automated system and method for withdrawing compounds from blood
WO2004022111A1 (en) * 2002-09-05 2004-03-18 Mitra Medical Technology Ab New composition use and method
US6884228B2 (en) 2001-03-06 2005-04-26 Baxter International Inc. Automated system adaptable for use with different fluid circuits
JP2008544847A (en) * 2005-07-06 2008-12-11 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ Method for producing separation matrix

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582386B2 (en) 2001-03-06 2003-06-24 Baxter International Inc. Multi-purpose, automated blood and fluid processing systems and methods
US6706008B2 (en) 2001-03-06 2004-03-16 Baxter International Inc. Automated system and method for withdrawing compounds from blood
US6884228B2 (en) 2001-03-06 2005-04-26 Baxter International Inc. Automated system adaptable for use with different fluid circuits
WO2004022111A1 (en) * 2002-09-05 2004-03-18 Mitra Medical Technology Ab New composition use and method
JP2008544847A (en) * 2005-07-06 2008-12-11 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ Method for producing separation matrix

Similar Documents

Publication Publication Date Title
JP3897985B2 (en) Manufacture of an adsorption device using an adsorbent for reducing the concentration of fibrinogen and / or fibrin
JPH0557015A (en) Adsorbent and sterilizing method therefor
JP3926573B2 (en) Adsorbent manufacturing method for reducing the concentration of fibrinogen and / or fibrin, adsorbent and use of the adsorbent for the manufacture of an adsorber
EP0179420B1 (en) Sterilization of adsorbent and column having improved storability including sterilized adsorbent for use in extracorporeal circulation treatment
JP3285441B2 (en) Adsorbent for lowering plasma viscosity of vasoocclusive disease plasma and apparatus for lowering plasma viscosity
JPS6319214B2 (en)
JPH0977790A (en) Adsorbent for antibody to glycolipid
JPH0323182B2 (en)
JPS63232845A (en) Adsorbent for low-density lipoprotein and method for producing the same
JPS62191042A (en) Blood coagulation factor viii adsorbent and method for purifying blood coagulation factor viii using same
JPH067430A (en) Blood treating adsorbent
JP2578588B2 (en) Method for improving storage stability of adsorption column for extracorporeal circulation treatment
JP3157026B2 (en) Adsorbent for blood purification
JPS62224362A (en) Adsorption column for extracorporeal remedy improved in storage stability
JPS59206045A (en) Adsorbent for lipoprotein of low specific weight
JPS6256782B2 (en)
JPS59139937A (en) Low-density lipoprotein adsorbent
JP3181343B2 (en) Method for producing adsorbent material for body fluid purification
JPH0547224B2 (en)
JP4443309B2 (en) Fibrinogen adsorbent III
JPH06233816A (en) Hemocatharsis adsorbent
JPS62244442A (en) Low specific gravity lipoprotein adsorbing material and its preparation
JPH0547223B2 (en)
JPS60114340A (en) Adsorbent for adsorption of low specific gravity lipoprotein
JPH05146509A (en) Hemoglobin adsorbent